MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma ; volume:4 ; number:1 ; day:30 ; month:9 ; year:2024 ; pages:1-8 ; date:12.2024
Communications medicine ; 4, Heft 1 (30.9.2024), 1-8, 12.2024
- Urheber
-
Claeys, Arne
Van den Eynden, Jimmy
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s43856-024-00612-w
- URN
-
urn:nbn:de:101:1-2412152113415.511588358555
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Claeys, Arne
- Van den Eynden, Jimmy
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy of malignant melanoma
Phenotypes and Genotypes of Melanoma Patients
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Development of MHC-dependent immunotherapy for gliomas
Computational immunology : from MHC-peptide binding to immunotherapy
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Beyond PD-1 Immunotherapy in Malignant Melanoma
Advances in predictive biomarkers for melanoma immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy of malignant melanoma
Phenotypes and Genotypes of Melanoma Patients
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Development of MHC-dependent immunotherapy for gliomas
Computational immunology : from MHC-peptide binding to immunotherapy
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Beyond PD-1 Immunotherapy in Malignant Melanoma
Advances in predictive biomarkers for melanoma immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy of malignant melanoma
Phenotypes and Genotypes of Melanoma Patients
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Development of MHC-dependent immunotherapy for gliomas
Computational immunology : from MHC-peptide binding to immunotherapy
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Beyond PD-1 Immunotherapy in Malignant Melanoma